2型糖尿病 中国就医指南

Type 2 Diabetes Mellitus (T2DM) is a chronic, progressive metabolic disorder characterized by persistent hyperglycemia resulting from insulin resistance in peripheral tissues—primarily skeletal muscle, liver, and adipose tissue—combined with relative insulin deficiency due to progressive beta-cell dysfunction in the pancreatic islets. Unlike type 1 diabetes, autoimmune destruction of beta cells is not central; instead, T2DM arises from complex interactions among genetic susceptibility, epigenetic modifications, and modifiable environmental drivers—including sedentary lifestyle, excessive caloric intake, obesity (particularly visceral adiposity), and aging. Pathophysiologically, insulin resistance impairs glucose uptake and promotes hepatic gluconeogenesis, while declining beta-cell mass and function reduce insulin secretion capacity, ultimately leading to sustained hyperglycemia and glucotoxicity that further accelerates beta-cell decline. Globally, T2DM affects over 537 million adults (2023 IDF Atlas), with prevalence projected to exceed 783 million by 2045. In China—the world’s largest diabetic population—over 141 million adults live with diabetes (12.4% age-standardized prevalence), and nearly half remain undiagnosed. Key risk factors include age ≥45 years, overweight or obesity (BMI ≥24 kg/m² in Asians), family history, physical inactivity, hypertension, dyslipidemia, history of gestational diabetes, polycystic ovary syndrome (PCOS), and urban residence with high processed-food consumption. Socioeconomic disparities significantly influence access to care and outcomes. Quality of life is profoundly impacted: patients report higher rates of fatigue, depression (2–3× increased risk), anxiety, sexual dysfunction, sleep disturbances, and reduced work productivity. Long-term microvascular complications—including diabetic retinopathy (leading cause of preventable blindness), nephropathy (a major cause of end-stage renal disease), and neuropathy (increasing risk of foot ulcers and amputations)—coexist with macrovascular threats such as coronary artery disease, stroke, and peripheral arterial disease. Cognitive decline and increased dementia risk are also well-documented. Effective management requires lifelong, person-centered strategies integrating medical nutrition therapy, structured physical activity, behavioral support, pharmacotherapy (e.g., metformin, SGLT2 inhibitors, GLP-1 receptor agonists), and regular monitoring of HbA1c, blood pressure, lipids, and organ-specific complications. Early diagnosis, individualized glycemic targets, and multidisciplinary care—including endocrinologists, dietitians, diabetes educators, ophthalmologists, and podiatrists—are critical to preserving functional independence and reducing premature mortality.

# 2型糖尿病治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：新诊断、HbA1c＜9.0%、无严重并发症者

• •基础管理（饮食运动+教育）：免费～300元/年（含门诊随访、营养师指导、血糖监测培训）
• •口服降糖药（二甲双胍/格列美脲/SGLT2i/DPP-4i等）：

- 进阶档（原研药/新型药物）：4,800–15,600元/年

• •检查检验费（年均）：空腹+餐后血糖（120元）、HbA1c（80元）、肝肾功+血脂（260元）、尿微量白蛋白（120元），合计约580元/年

二、胰岛素治疗方案

适用人群：HbA1c≥9.0%、口服药失效、存在明显高血糖症状或妊娠期合并症

• •基础胰岛素（甘精/德谷）：2,400–6,000元/年（含注射笔+针头）
• •强化方案（每日多次注射/胰岛素泵）：8,000–22,000元/年（含动态血糖监测CGM，国产设备起）
• •术前/调整期检查：C肽+胰岛素释放试验（320元）、酮体检测（60元）

三、特殊复杂/并发症治疗

• •糖尿病肾病（CKD 3–4期）：RAS抑制剂+SGLT2i+专科随访，年费用1.2万–3.5万元（含eGFR监测、24h尿蛋白定量）
• •糖尿病足高危/溃疡：多学科联合管理（内分泌+血管外科+创面修复），单次住院费用1.8万–6.2万元
• •严重低血糖/脆性糖尿病：闭环胰岛素泵系统（国产），设备+耗材首年约4.5万–7.8万元

四、方案快速选择指南

• •预算≤3,000元/年：首选二甲双胍+生活方式干预+基础检验
• •预算8,000–20,000元/年：推荐SGLT2i或GLP-1RA联合治疗+CGM监测
• •合并中重度并发症：立即启动胰岛素强化+多学科协作，优先选择医保目录内药物与耗材